[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Nacional de Cancerologia de Mexico\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":351},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,49,75,102,122,152,173,203,223,247,273,300,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100534442","nitroglycerin-plus-radiotherapy-versus-conventional-radiotherapy-in-patients-with-lung-cancer-100534442",false,"NCT06238882","Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.","A Phase III Study Comparing Concurrent Nitroglycerin With Radiation Therapy vs Radiation Therapy Alone in Patients With Non-small Cell Lung Cancer With EGFR Mutations and Brain Metastases.","Inclusion Criteria:\n\n* Patients diagnosed with advanced non-small cell lung cancer (which includes de novo stage IIIB-IV, according to the 8th edition AJCC, or recurrent disease), documented by histology and\u002For cytology.\n* Presence of brain metastases, candidates for treatment with holocranial radiation therapy.\n* Documented EGFR sensitivity mutation.\n* Disease measurable by criteria: The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM).\n* 18 years and up.\n* Functional status, by ECOG scale 0-2\n* Life expectancy at least 12 weeks.\n* Not receive vasodilator treatment as calcium channel blockers.\n* Electrocardiogram\n* Neutrophil count 1.5 x 103\u002Fmm3, platelet count \\>100 x (103\u002Fmm3).\n* Serum bilirubin should be 1.5 of the upper normal limit (ULN, upper normal limit).\n* AST and\u002For ALT 2 ULN (or 5 x ULN in patients with liver metastases).\n* Serum creatinine 1.5 (ULN), or creatinine clearance 60ml\u002Fmin.\n* Ability to comply with study and follow-up procedures.\n* Informed written (signed) consent to participate in the study.\n* Have tumor tissue (paraffin blocks from diagnostic biopsy) obtained before systemic treatment\n\nExclusion Criteria:\n\n* Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, ischemic heart disease, liver, kidney disease).\n* Patients with a history of allergy to glyceryl tinistate\n* Any other malignant pathology within the previous 5 years (except for cervical carcinoma in situ or basal-cell skin cancer, treated appropriately).\n* Pregnant and\u002For breastfeeding women.\n* Meningeal carcinomatosis corroborated by cytopathological study.\n\nDisposal Criteria:\n\n* Failure to follow protocol rules.\n* Loss of patient follow-up.\n* Patients who express their desire not to continue the study.\n* Patients with unacceptable toxicity","ALL","18 Years","85 Years",{"count":20,"type":21},74,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this interventional phase III clinical trial is to evaluate objective intracranial response rate (iORR) after a treatment with total cranial radiation therapy plus concomitant transdermal nitroglycerin (NTG) addition or total cranial radiation therapy only in patients with stage IV non-small cell lung cancer with brain metastases and EGFR mutation. The main questions it aims to answer are:\n\nDetermine progression-free survival (PFS) to CNS and overall survival (OS). Evaluate and compare the quality of life (QoL) of patients during and after treatment.\n\nEvaluate the cognitive function of patients before, during and after treatment. Evaluate treatment-associated toxicity to grade adverse treatment events Evaluation of HIF1α, VEGF and ROS1 in peripheral blood before and after nitroglycerin treatment.\n\nAll participants will have laboratory tests at the beginning and end of radiation therapy. Cranial MRI will be performed prior to treatment and 12 weeks after the end of treatment, then every 16 weeks until intracranial progression. Patients in the interventional group will be given 36 mg patches of transdermal nitroglycerin for 24 hours with a 12-hour rest interval during treatment with radiation therapy. The control group will only receive total cranial radiation therapy at the same doses and with the same schedule.",[27,28,29],"Non-small Cell Lung Cancer","Brain Metastases","EGFR Gene Mutation",[31,32,33,34,35],"Radiation therapy","Nitroglycerin","Brain metastases","EGFR mutation","Non-small cell lung cancer","RECRUITING","2026-04-06",{"date":39,"type":40},"2026-04-09","ACTUAL",{"date":42,"type":40},"2023-02-23",{"date":44,"type":21},"2027-02-15",{"name":46,"class":47},"Instituto Nacional de Cancerologia de Mexico","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100504796","phase-3-glutamine-plus-l-reuteri-prevents-tki-therapy-diarrhea-in-patients-with-nsclc-100504796","NCT05852990","Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC","Effect of Glutamine Plus Lactobacillus Reuteri Added to an Astringent Diet in Preventing Diarrhea Caused by Tyrosine Kinase Inhibitors (TKIs) in Patients With Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Both sexes\n* ≥ 18 years old\n* Pathologically confirmed diagnosis of NSCLC\n* Stage IIIB - IV by the American Joint Committee of Cancer Version 8.\n* Candidates to receive EGFR-TKI treatment (1st \\& 2nd generation TKI)\n* ECOG score ≤ 2\n* Life expectancy \\> eight weeks\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Patients who cannot attend the first protocol appointment.\n* Treatment with other anti-cancer therapy\n* Participating in other clinical trials in the former four weeks\n* Any other serious condition or uncontrolled active infection, altered mental status or psychiatric disorder that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.\n* Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.\n* Active HIV infection.\n* Breastfeeding.","80 Years",{"count":58,"type":21},28,[60],"PHASE3","This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy.\n\nThe main question it aims to answer is ¿What is the effect of glutamine plus L. reuteri added to an astringent diet in preventing diarrhea generated by TKI therapy?\n\nPatients will receive an astringent diet supplemented with 10 grams of glutamine and L. reuteri (100 million CFU). Researchers will compare the Glutamine plus L. reuteri diet with a standard astringent diet to see if TKI therapy diarrhea is prevented.",[63],"Non-Small Cell Lung Cancer With EGFR Mutation",[65,34,66,67,68],"Non-Small Cell Lung Cancer","Glutamine","Lactobacillus reuteri","standard-care diet",{"date":39,"type":40},{"date":71,"type":40},"2022-03-01",{"date":73,"type":21},"2027-12-12",{"name":46,"class":47},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100494040","phase-1-alectinib-pharmacokinetic-in-patients-with-nsclc-100494040","NCT05713006","Alectinib Pharmacokinetic in Patients With NSCLC","A Phase I\u002FII Open-label Clinical Trial to Evaluate the Pharmacokinetics of Alectinib With Sequential Dose Escalation in Patients Diagnosed With ALK-rearranged Advanced Non-small Cell Lung Cancer.","Inclusion Criteria:\n\n* Both sexes\n* ≥ 18 years old\n* Pathologically confirmed diagnosis of NSCLC\n* Stage IIIB - IV by the American Joint Committee of Cancer Version 8.\n* Recurrent disease (at least 180 days from curative intent treatment)\n* ALK rearrangements tested by FDA-approved tests (IHQ or FISH)\n* Karnofsky PS scale ≥ 70%\n* Having received first-line treatment with anti-ALK inhibitors and one previous line of platinum-based chemotherapy.\n* Measurable disease as referred by RECIST version 1.1\n* Symptomatic brain metastases could receive prior treatment with radiotherapy or surgery for at least two weeks before treatment initiation.\n* Asymptomatic brain metastases could not receive local therapy before study inclusion.\n* Negative highly sensitive pregnancy test (serum or urine) within 72 days before first dose intervention.\n* Sexually active patients should use a contraceptive method with a failure rate of less than 1% per year.\n* Signed written informed consent\n* Adequate organ function (hematological, liver, and renal function)\n* Life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Carcinomatous meningitis confirmed by a positive CRL cytology or highly suspicious brain MRI.\n* Previous malignancies except for any carcinoma in-situ\n* Treatment with other anti-cancer therapy\n* Participating in other clinical trials in the former four weeks\n* Any other serious condition or uncontrolled active infection, altered mental status, or psychiatric condition that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.\n* Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.\n* Active HIV infection.\n* Breastfeeding.",{"count":83,"type":21},45,[85,86],"PHASE1","PHASE2","This interventional study aims to determine the pharmacokinetics of orally administered alectinib with dose escalation from 300 mg to 600 mg twice daily in Mexican patients with advanced ALK-positive NSCLC.\n\nThe main question it aims to answer is: what will be the peak plasma concentrations of alectinib following sequential dose escalation (300, 450, and 600 mg BID) over nine weeks of pharmacokinetic evaluation (phase I) in Mexican patients with advanced ALK-rearranged NSCLC?\n\nIn phase I (on days 0, 21, and 42), oral alectinib will be administered twice per day (BID) to patients with ALK-positive NSCLC; starting with 300 mg BID in 21-day cycles and dose escalation in 150 mg increments until 600 mg BID. Blood samples will be taken before and after administration of each dose (on days 1, 22, and 43). The primary endopoints in phase I will be dose-limiting toxicity (DLT) and PK parameters (Cmax. maximum plasma concentration; Tmax: time to reach maximum concentration: AUC 1-12: area under plasma ocncentrations-time curve steady-state concentration). At the end of the last blood collection (at day 43), the evaluation of each cycle will be at 600 mg, and the participant will be discharged to continue their treatment on an outpatient basis. Phase one will finish on day 63 of the study.\n\nIn phase II, the chosen BID dose based on the phase I portion will be administrated until disease progression, development of unacceptable side effects, or withdrawal of consent. The primary endpoint in phase 2 is the overall response rate (ORR) per RECIST V.1.1.",[89,90],"Non-small Cell Lung Cancer Stage IIIB","ALK Gene Mutation",[92,93,94],"alectinib","positive-ALK","non small cell lung cancer",{"date":96,"type":40},"2026-04-08",{"date":98,"type":40},"2022-05-01",{"date":100,"type":21},"2027-12-01",{"name":46,"class":47},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":48},"100473507","phase-3-metformin-plus-tyrosine-kinase-inhibitors-for-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-mutations-100473507","NCT05445791","Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone for Patients With Advanced Non-small Cell Lung Cancer and EGFR Mutations: Phase 3 Randomized Clinical Trial","METLUNG","Inclusion Criteria:\n\n1. Patients with a histologically confirmed diagnosis of non-small cell lung cancer (stage IIIB-IV) according to the American Joint Committee on Cancer (AJCC) eight edition.\n2. Measurable disease by RECIST 1.1.\n3. 18 years of age or older.\n4. Functional status 0-2 as assessed by Eastern Cooperative Oncology Group (ECOG) scale.\n5. Life expectancy of minimum12 weeks.\n6. Patients with non-small cell lung cancer and a documented EGFR sensitizing mutation.\n7. Patients without previous EGFR-TKI treatment. Previous use of chemotherapy is allowed with a washout period of at least 6 months.\n8. Patients with asymptomatic brain metastases, or if symptoms are present treatment with radiotherapy (whole brain radiotherapy, stereotactic radiosurgery) or surgery must be administered.\n9. Neutrophil count ≥1.5 x 103\u002Fmm3, and platelet count \\>100 x (103\u002Fmm3).\n10. Serum bilirubin ≤1.5 the superior upper limit.\n11. Aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) ≤ 2 superior upper limit (or ≤ 5 times the superior upper limit in patients with liver metastases).\n12. Serum creatinine ≤ 1.5 superior upper limit, or creatinine clearance ≥ 60ml\u002Fmin.\n13. Full ability to complete all study procedures and follow up.\n14. Women with child-bearing potential must have a negative pregnancy test within 72 hours of treatment start.\n15. Patients with reproductive potential must use effective contraception.\n16. Signed informed consent for participation in the study.\n17. Availability of tumor tissue (pre-treatment biopsy) to determine LKB1 and AMPK status.\n\nExclusion Criteria:\n\n1. Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart disease, hepatic diseases, renal diseases).\n2. Patients previously treated with an EGFR-TKI.\n3. Patients diagnosed with any other neoplastic disease in the previous 5 years (except in situ cervical carcinoma or basocellular skin cancer, treated accordingly).\n4. Patients unable to receive oral medication, who require IV nourishment, or who underwent surgical procedures with affect nutrient absorption, or with an active peptic ulcer.\n5. Pregnant or lactating women.\n6. Patients diagnosed with type 2 diabetes or a glycated hemoglobin ≥ 6.5%.\n7. Patients being currently treated with metformin.",{"count":111,"type":21},312,[60],"Lung cancer is the most common neoplastic disease globally, with over 2 million new cases annually, accounting for 11.6% of all cancer diagnoses. It remains the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) makes up 80-85% of lung cancer cases, with most patients diagnosed at an advanced stage. Five-year survival rates are low, ranging from 8-18% worldwide.\n\nAdvances in molecular biology have led to the identification of therapeutic targets in NSCLC. One of the most studied is the epidermal growth factor receptor (EGFR), a key regulator of tumor cell functions and a focus of targeted therapy development. EGFR mutations occur in about 15% of NSCLC cases globally but reach up to 34% in Mexico. Patients with these mutations are treated with tyrosine kinase inhibitors (TKIs), which improve response rates and progression-free survival (PFS) over chemotherapy. However, resistance to TKIs typically develops, prompting the need for strategies to overcome this challenge and extend PFS.\n\nUp to 30% of NSCLC patients have somatic mutations in the liver kinase B1 (LKB1) gene, a tumor suppressor that inhibits mTOR. In one study, 24 patients with LKB1 expression treated with metformin plus TKIs showed significantly improved overall survival. LKB1 activates AMP-activated protein kinase (AMPK), which regulates cell cycle and survival in NSCLC. Loss of LKB1 reduces AMPK activation and increases tumor necrosis following bevacizumab treatment. A study of 99 NSCLC samples linked high AMPK expression to poorer survival, though its role in metformin response is unclear.\n\nMetformin, a biguanide used for type 2 diabetes, has shown anticancer properties. Studies suggest metformin reduces cancer incidence and mortality. In vitro, it induces G0\u002FG1 cell cycle arrest and counters TKI resistance due to epithelial-mesenchymal transition (EMT). Retrospective studies support its benefit in NSCLC, and prospective trials of metformin plus TKIs have yielded mixed results.\n\nThis phase 3 randomized study aims to evaluate PFS in NSCLC patients with EGFR mutations treated with TKIs plus placebo versus TKIs plus metformin.",[115],"Non Small Cell Lung Cancer",{"date":39,"type":40},{"date":118,"type":40},"2021-07-15",{"date":120,"type":21},"2027-07-14",{"name":46,"class":47},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":151},"100347441","phase-2-prophylactic-inhaled-steroids-to-reduce-radiation-pneumonitis-frequency-and-severity-in-lung-cancer-patients-100347441","NCT03803787","Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients","Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Non-small Cell Lung Cancer Patients","Inclusion Criteria:\n\n* Patients with non-small cell lung cancer (NSCLC) with unresectable locally advanced or metastatic disease (IIIA, IIIB or IV) of the classification tumor node, metastasis (TNM) of malignant lung tumors, 7th edition.\n* NSCLC patients candidates for concomitant treatment (chemotherapy plus radiotherapy or target therapy plus radiotherapy).\n* Evidence of measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, Karnofsky 70-100.\n* Life expectancy of \\> 4 months at the time of screening\n* Patients with the ability to comply with the study and follow-up procedures.\n* Patients with previous surgery less than four weeks.\n* Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures.\n\nExclusion Criteria:\n\n* Unstable systemic disease: active infection, heart, liver, kidney or metabolic disease; including uncontrolled chronic lung disease.\n* Patients treated with systemic or inhaled corticosteroids.\n* Patients of reproductive age without a family planning method, pregnant or lactating.\n* Previous diagnosis of Pneumonitis with toxicity grade ≥ 2 by CTCAE v4.0 or RTOG scale.\n* Patients with disease progression.\n* Inspiratory flow \\\u003C 90 liters \u002F min.\n* Discontinue of Treatment","75 Years",{"count":131,"type":21},72,[86],"This randomized clinical study aims to assess whether prophylactic treatment with inhaled steroids in patients with locally advanced or concomitantly treated non-small cell lung carcinoma who are candidates for combination treatment with QT\u002FRT or IMT + QT\u002FRT.\n\nThe main questions it aims to answer are:\n\nWhether prophylactic treatment decreases the severity of NPR on CTCAE v4.0 and RTOG scales.\n\nWhether inhaled steroid use modifies the response to radiation therapy treatment compared to patients who do not receive prophylactic inhaled steroids.",[135],"Radiation Pneumonitis",[65,137,138,139,140,141,142,143,144,145],"Radiation Pneumonia","Lung cancer treatment","Respiratory Tract Neoplasms","Radiation fibrosis","Thoracic Neoplasms","Lung Diseases","Radiation Injury with Fibrosis","Radiation Fibrosis of Lung","Lung Injury",{"date":96,"type":40},{"date":148,"type":40},"2018-09-01",{"date":100,"type":21},{"name":46,"class":47},2,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":172,"locationsCount":48},"100284125","pulmonary-rehabilitation-in-advanced-non-small-cell-lung-cancer-patients-100284125","NCT02978521","Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients","Effect of a Pulmonary Rehabilitation Program on Skeletal Muscle Mass, Pulmonary Function, Inflammatory Response and Overall Survival on Patients Diagnosed With Non-small-cell Advanced Cancer","Inclusion Criteria:\n\n* Confirmed diagnosis of advanced non-small-cell lung cancer\n* Good performance status (ECOG 0-1)\n* Life expectancy \\>12 weeks\n* Eligible to receive treatment with chemotherapy or tyrosinkinase inhibitors\n* Recent electrocardiogram without evidence of arrythmia\n\nExclusion Criteria:\n\n* Symptomatic brain metastasis\n* Uncontrolled pain (Visual Analog Scale \\>5)\n* Uncontrolled hypertension (\\>140\u002F100mmHg)\n* Practice of regular moderate to intense physical activity at least 3 day\u002Fweek\n* Not residents of Mexico City or unable to attend to therapy sessions","70 Years",{"count":161,"type":21},94,[24],"Lung cancer (LC) is usually diagnosed in advanced stages and continues to be the leading cause of cancer related deaths worldwide. Cancer cachexia are frequent among patients with LC affecting up to 80% of patients with advanced stage disease, and it has been related with higher risk of complications, length of hospital stay, and worst overall survival. During cancer cachexia, both muscle and fat mass can be wasted, however, the loss of muscle mass has been associated to higher treatment related toxicity, loss of functional status, shorter progression free survival and overall survival in different types of cancer under various treatments. Hence, preservation of muscle mass and function should be an important focus of the multidisciplinary treatment of patients with LC.\n\nPulmonary rehabilitation (PR) has been known to improve pulmonary function, reduce fatigue and improve exercise tolerance in patients with LC undergoing curative surgery. However, few studies have focused on the efficacy of PR on patients with advanced cancer undergoing palliative care with chemotherapy or targeted therapies.",[165,166,167],"Pulmonary Rehabilitation","Sarcopenia","Quality of Life",{"date":96,"type":40},{"date":170,"type":40},"2016-08-05",{"date":73,"type":21},{"name":46,"class":47},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":181,"sex":16,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":48},"100557233","lung-cancer-screening-program-in-mexico-100557233","NCT06535451","Lung Cancer Screening Program in Mexico","Lung Cancer Early Detection With Low-dose Computed Tomography in High-risk Individuals: Experience in Mexico","DETECTO","Inclusion Criteria:\n\nEligible participants over fifty years old and one of the next criteria:\n\n* Current smokers (\\>20 pack-years)\n* Former smokers (\\>20 pack-years) who have quit within the past 15 years,\n* Non-smokers exposed to wood smoke more than 100 hours\u002Fyear\n* Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).\n\nExclusion Criteria:\n\n* Subjects who cannot be examined by tomography due to physical limitations such as weight.\n* History of any type of cancer within the last five years, except non-melanoma skin cancer.\n* Symptoms consistent with some malignant neoplasm.\n* People with a poor physical-emotional condition that reduces their life expectancy or does not ensure adherence to the study.\n\nElimination Criteria\n\n• Withdrawal of informed consent",true,"50 Years",{"count":184,"type":21},1000,"OBSERVATIONAL","This prospective study aims to detect early-stage lung cancer using low-dose computed tomography (LDCT) in Mexicans aged 50 or older who are current or former heavy smokers, non-smokers exposed to significant wood smoke, or diagnosed with COPD. Annual LDCT, spirometry, and serum biomarker tests will be conducted over 3 years, and a follow-up lasting up to 10 years.",[188],"Lung Cancer",[190,191,192,193,194],"Lung cancer screening","Early detection","Lung cancer","Low-dose CT","High-risk population","2025-12-17",{"date":197,"type":40},"2025-12-24",{"date":199,"type":40},"2022-03-24",{"date":201,"type":21},"2027-03-24",{"name":46,"class":47},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":185,"phases":4,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":48},"100265385","impact-of-fat-free-mass-in-the-carboplatin-calculated-dose-and-chemotherapeutic-toxicity-in-patients-with-advanced-nsclc-100265385","NCT02734069","Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC","Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n* Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)\n* Candidates for treatment with carboplatin plus paclitaxel 1st line\n* Performance status (ECOG 0-2)\n* Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)\n* Normal renal ultrasound prior to initiation of treatment\n\nExclusion Criteria:\n\n* Patients with renal impairment (KDOQI 3-5)\n* Patients who do not have computed tomography study at baseline\n* Uncontrolled blood pressure (\\> 140 mmHg)\n* Uncontrolled diabetes (\\> 130 mg \u002F dL)\n* Obstruction in kidney (s) or ureter (s)\n* Dehydrated patients\n* Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.\\> 1 month)",{"count":211,"type":21},132,"This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin\u002FPaclitaxel in advanced NSCLC.",[188,166,214],"Toxicity",[216],"carboplatin",{"date":197,"type":40},{"date":219,"type":40},"2016-02",{"date":221,"type":21},"2027-12",{"name":46,"class":47},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":231,"targetDuration":233,"studyType":185,"phases":4,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":48},"100552762","scale-of-therapeutic-adherence-to-respiratory-rahabilitation-for-lung-cancer-100552762","NCT06477302","Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer","Construction and Psychometric Properties of the Therapeutic Adherence Scale for Respiratory Rehabilitation in Lung Cancer (STA-RR-LC).","STA-RR-LC","Inclusion Criteria:\n\n* Patients diagnosed with lung cancer (SCLC and NSCLC).\n* Over 18 years of age.\n* Voluntary participation by understanding and accepting the informed consent letter.\n* Patients undergoing Respiratory Rehabilitation treatment with one month assessment and follow-up.\n* Patients in active medical treatment.\n* Any clinical stage.\n* Karnofsky Index ≥ 70.\n\nExclusion Criteria:\n\n* Severe hearing or visual problems that prevent them from understanding the instructions and answering the instruments (this will be identified as reported in the clinical record file).\n* Severe psychiatric conditions (schizophrenia or psychotic disorders) and\u002For addiction to any psychoactive substance (this will be identified as reported in the INCanet file).\n* Attentional or memory problems that prevent them from understanding the instructions and answering the instruments (this will be identified as reported in the INCanet file).",{"count":232,"type":21},281,"1 Day","The goal of this non experimental, transversal instrument study is to Construct and determine the reliability and validity of the Scale of Therapeutic Adherence for Respiratory Rehabilitation in Lung Cancer in Mexican patients with a lung cancer diagnosis.\n\nThe main question it aims to answer is: What is the reliability and validity of the Scale of Therapeutic Adherence for Respiratory Rehabilitation in Lung Cancer of the patients with this diagnosis that are currently undergoing an assessment or follow up program of Respiratory Rehabilitation?\n\nThe Scale of Therapeutic Adherence for Respiratory Rehabilitation in Lung Cancer (STA-RR-LC) will be psychometrically valid and reliable for the evaluation of therapeutic adherence on patients with lung cancer that are undergoing an assessment or follow up of Respiratory Rehabilitation.Participants will be asked to fill out an Identification card and fill out the fifty-six items presented on the STA-RR-LC.",[188],[237,238,188],"pulmonary rehabilitation","therapeutic adherence","2025-12-16",{"date":241,"type":40},"2025-12-23",{"date":243,"type":40},"2023-06-23",{"date":245,"type":21},"2027-06-23",{"name":46,"class":47},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":254,"minAge":17,"maxAge":56,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":48},"100583982","laparoscopic-interval-cytoreductive-surgery-in-advance-ovarian-cancer-100583982","NCT06883409","Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer","Efficiency of Laparoscopic Interval Cytoreductive Surgery After Neoadjuvant Chemotherapy in Patients With Stage III and IV Epithelial Ovarian Cancer","Inclusion Criteria:\n\n* Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV\n* Partial and complete response to treatment with QTNA after 3-4 cycles, evaluated by PET-CT imaging study, patients that the functional unit decides to incorporate into the project.\n* Ca 125 which will have to be less than 200\n* ECOG 0 to 2 without medical contraindication to perform surgery (≤ ASA 2 or ≤ Goldman 2).\n\nExclusion Criteria:\n\n* Partial response with persistence of ascites or pleural effusion.\n* With unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates \\>2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction).","FEMALE",{"count":256,"type":21},33,[24],"This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.",[260],"Ovarian Neoplasms",[262,263,264],"Minimal invasive surgery","interval debulking surgery","advance ovarian cancer","2025-03-24",{"date":267,"type":40},"2025-03-26",{"date":269,"type":40},"2022-05-19",{"date":271,"type":21},"2025-12-30",{"name":46,"class":47},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":48},"100548556","ceftolozanetazobactam-vs-piperacillintazobactam-for-the-treatment-of-bacteremia-in-hemato-oncological-patients-100548556","NCT06422533","Ceftolozane\u002FTazobactam vs. Piperacillin\u002FTazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","Ceftolozane\u002FTazobactam vs. Piperacillin\u002FTazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever: Non-inferiority Study","Inclusion Criteria:\n\n* All patients \\>18 years old\n* Diagnosis of any hematological malignancy\n* Severe neutropenia (polymorphonuclear \\\u003C500 cells\u002Fmm3)\n* Fever (≥38.3 degrees Celsius in one measure, or ≥38 degrees Celsius in at least two measures)\n* Median arterial pressure ≥65 mmHg on admission\n* A life expectancy ≥ 5 days\n* Agree to participate in the study\n\nExclusion Criteria:\n\n* Known hypersensitivity to cephalosporins or anaphylaxis with beta-lactams\n* Clinical signs related to hemodynamic instability\n* Concomitant use of another antibiotic with activity against Gram-negatives (except Trimethoprim\u002FSulfamethoxazole (TMP\u002FSMX) as prophylaxis for P. jirovecii\n* Patients with end-stage chronic renal failure (\\\u003C10 ml\u002Fmin by creatinine clearance-ACCr) or on renal replacement therapy.\n* Patients with grade IV mucositis",{"count":281,"type":21},226,[24],"Patients with hematological malignancies receive highly myelotoxic chemotherapy regimens that cause periods of severe myelosuppression, which places them at high risk of developing bacteremia.\n\nAt a global level, a very significant increase in multidrug-resistant (MDR) Gram-negative microorganisms, particularly Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL) and MDR P.aeruginosa, have been described during the last decade. Among the strategies to reduce bacterial resistance, ceftolozane\u002Ftazobactam (C\u002FT) as a \"carbapenem-sparing\" antibiotic has been proposed.\n\nC\u002FT has broad-spectrum activity since it has action against ESBL-producing Enterobacteriaceae and MDR P. aeruginosa. Studies carried out in the real world using this antibiotic in patients with hematological malignancies have demonstrated clinical success in reports and case series, considered a therapeutic option in patients with Enterobacteriaceae and P. aeruginosa infections, particularly in MDR pathogens.\n\nAt the National Cancer Institute (in Spanish, Instituto Nacional de Cancerologia), Gram-negative bacilli have been identified for more than 20 years as the pathogens most frequently associated with bacteremia. Escherichia coli occupies the first place in 25% (41% ESBL), followed by Klebsiella spp. in 5.6% (11.2% ESBL) and P. aeruginosa in 5.6% (11.2% MDR). The protocol for approaching and treating hematological malignancy patients with severe neutropenia and fever is to initiate an antimicrobial regimen with piperacillin\u002Ftazobactam (P\u002FT). In patients who persist with fever after 48 to 72 hours of starting antibiotics, who present with clinical deterioration, or in whom P\u002FT-resistant bacteria are identified, this is escalated to carbapenem.\n\nTherefore, it is proposed to compare the clinical and microbiological response in patients with hematological malignancies who present with severe neutropenia and fever and who present clinical data of bacteremia, with empirical treatment with C\u002FT vs. P\u002FT, trying to reduce the use of carbapenems in this group of patients.",[285,286],"Hematologic Neoplasms","Neutropenia",[288,289,290,291],"ceftolozane\u002Ftazobactam","piperacillin\u002Ftazobactam","neutropenia","hematologic neoplasms","2024-06-02",{"date":294,"type":40},"2024-06-04",{"date":296,"type":40},"2023-11-07",{"date":298,"type":21},"2025-08-30",{"name":46,"class":47},{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":254,"minAge":17,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":310,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":48},"100523063","improving-lifestyle-behavior-by-joven-fuerte-y-saludable-multidisciplinary-program-100523063","NCT06090747","Improving Lifestyle Behavior by \"Joven, Fuerte y Saludable\" Multidisciplinary Program.","Efecto de Una intervención Multidisciplinaria de Estilo de Vida Sobre el Exposoma de Pacientes premenopáusicas Con cáncer de Mama Estadios I-III.","Inclusion Criteria:\n\n* Women diagnosed with stage I-III BC, confirmed by pathology and image at the INCAN\n* Candidates for multidisciplinary treatment including surgery, chemotherapy, and\u002For hormonal treatments.\n* Signed the informed consent form\n* Have access to a mobile phone or any electronic device with an active internet connection to receive the program information.\n\nExclusion Criteria:\n\n* Patients with inflammatory cancer\n* Those with cardiomyopathy or ventricular dysfunction (NYHA \\>II), arrythmia secondary to left ventricular ejection alterations that requires medication, previous myocardial infarction, or angina pectoris in the last six months\n* Receiving treatment for cardiovascular or cerebrovascular disease, inflammatory bowel disease, malabsorption syndrome, rheumatoid arthritis, lupus, thyroid diseases, or Cushing syndrome\n* Unable to walk for at least 1 km\n* Have cardiovascular, respiratory, or musculoskeletal diseases that impede physical activity\n* Pregnant or breastfeeding\n* Have psychiatric conditions impeding active participation in this protocol\n* Do not understand Spanish","40 Years",{"count":309,"type":21},146,[24],"Breast cancer is the leading cause of mortality in women worldwide. Latin-American women are diagnosed at younger ages, in advanced stages, and with aggressive molecular subtypes. Lifestyle seems related to these aggressive conditions and worse outcomes. The present study seeks to evaluate the effect of a hybrid multidisciplinary intervention for implementing a healthy lifestyle to modify the personal and internal exposome of young women with breast cancer. This randomized controlled experimental study with two groups:\n\nGroup 1: Hybrid multidisciplinary lifestyle education intervention. Group 2: Individualized hybrid multidisciplinary lifestyle interventions. The multidisciplinary lifestyle intervention program includes oncology, nutrition, physiotherapy, and psychology interventions.",[313],"Breast Neoplasm",[315,316,317,318],"Multidisciplinary","Intervention","Lifestyle","Breast Cancer","2023-10-13",{"date":321,"type":40},"2023-10-19",{"date":323,"type":40},"2023-03-09",{"date":325,"type":21},"2028-12-31",{"name":46,"class":47},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":254,"minAge":17,"maxAge":159,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":48},"100306895","phase-2-hipec-in-ovarian-carcinoma-clinical-stage-iiic-and-iv-during-interval-laparotomy-100306895","NCT03275194","HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy","Hyperthermic Intraperitoneal Chemotherapy in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy. Phase II Study","Inclusion Criteria:\n\n1. Patients younger than 70 years\n2. Patient with a diagnosis of high grade serous carcinoma of the ovary and low-grade endometrioid corroborated by histopathological study.\n3. Clinical stage IIIC and IVA (cytology-positive pleural effusion) who have received induction chemotherapy 3 or 4 cycles of CARBOPLATIN and PACLITAXEL.\n4. Partial response to treatment with chemotherapy and evaluated by computed tomography (RECIST-see below) and response of at least 50% by serum determination of CA-125 antigen.\n5. Signature of informed consent.\n6. Optimal cytoreduction with residual tumor less than 2.5 mm during interval surgery\n7. ECOG less than or equal to 1\n8. Adequate renal, cardiac, hepatic, bone marrow and lung function evaluated preoperatively with the following parameters:\n\n   a) Hb equal to or greater than 10 g \u002F L (pre-treatment transfusion is permitted to achieve this hemoglobin level) b) Leukocytes Greater than 3000 \u002F mm3 (c) Platelets equal to or greater than 100 000 \u002F mm3 (d) total bilirubin less than 1.5 times greater than the normal value e) Hepatic transaminases less than 1.5 times higher than normal value f) Creatinine \\\u003C1.2 g \u002F dl. In case of being elevated the measured purification should be greater than 60mL \u002F min according to Cockroft's formula.\n\n   g) Albumin greater than 3gr \u002F dl. h) Left Ventricle Ejection fraction per cardiac echography greater than 55% 9). Sugarbaker carcinomatosis index less than 20\n\nExclusion Criteria:\n\n1. Patients with heart failure, ischemic heart disease\n2. Previous history of treatment with chemotherapy for some other neoplasia\n3. History of neuropsychiatric disease\n4. Patients with intra operative bleeding that condition hemodynamic instability.\n5. Patient requiring more than 2 intraoperative anastomosis",{"count":335,"type":21},100,[86],"Ovarian cancer is the leading cause of gynecological cancer mortality, with no current screening method effective for early diagnosis, with 75% of advanced stage patients being detected. Not all patients are candidates for standard treatment, which is primary cytoreduction followed by adjuvant chemotherapy, due to the advanced process. A subgroup of patients will receive neoadjuvant chemotherapy followed by interval surgery, which allows higher rates of optimal cytoreduction with low morbidity and mortality. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a therapeutic option that is used in pathologies of peritoneal dissemination, whose morbidity and mortality has been reported in several series and is promising as a management option for ovarian cancer, so it is necessary to evaluate morbidity and mortality that conditions this modality of treatment as well as if it impacts on the quality of life of the patients to whom they are performed, which will allow offering our patients an option of additional treatment to the standard.",[339,340,341,342],"HPEC","Ovarian Cancer","Women's Health: Neoplasm of Ovary","Chemotherapy Effect","2023-04-26",{"date":345,"type":40},"2023-04-28",{"date":347,"type":40},"2017-09-02",{"date":349,"type":21},"2026-12-01",{"name":46,"class":47},""]